Similar articles

• Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

  Robbins AS, Clarke CA. Robbins AS, et al. J Natl Cancer Inst. 2007 Dec 5;99(23):1815; author reply 1816-7. doi: 10.1093/jnci/djm209. Epub 2007 Nov 27. J Natl Cancer Inst. 2007. PMID: 18042938 No abstract available.
• Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

  Ponti A, Rosso S, Zanetti R, Ricceri F, Tomatis M, Segnan N. Ponti A, et al. J Natl Cancer Inst. 2007 Dec 5;99(23):1817-8; author reply 1819. doi: 10.1093/jnci/djm225. Epub 2007 Nov 27. J Natl Cancer Inst. 2007. PMID: 18042935 No abstract available.
• Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

  Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Glass AG, et al. J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61. doi: 10.1093/jnci/djm059. Epub 2007 Jul 24. J Natl Cancer Inst. 2007. PMID: 17652280
• [Ductal carcinoma in situ of the breast].

  Barth A, Köchli OR, Brenner RJ, Giuliano E, Castiglione M. Barth A, et al. Schweiz Med Wochenschr. 1995 Jan 28;125(4):103-12. Schweiz Med Wochenschr. 1995. PMID: 7878398 Review. German.
• Screening for breast cancer in England: a review.

  Hogben RK. Hogben RK. Curr Opin Obstet Gynecol. 2008 Dec;20(6):545-9. doi: 10.1097/GCO.0b013e3283186fab. Curr Opin Obstet Gynecol. 2008. PMID: 18989129 Review.